Review paper
Sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection
Abstract
The landscape of HCV treatment has been entirely transformed due to the development of direct-acting antivirals (DAAs), but there are limited data guiding salvage therapy in patients who previously failed an NS5A inhibitor-containing DAA regimen. We review the preclinical and clinical data for sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), an interferon-free, oral, once daily, pan-genotypic treatment for chronic HCV infection. This...
Paper Details
Title
Sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection
Published Date
Jan 24, 2019
Journal
Volume
14
Issue
2
Pages
61 - 71